Hepatitis and HIV Care

Dear Colleague:

May is Hepatitis Awareness Month in the United States, and May 19, 2019, is Hepatitis Testing Day.  The Health Resources and Services Administration’s (HRSA) HIV/AIDS Bureau (HAB) has a long-standing commitment to people with HIV who are coinfected with hepatitis C.  HRSA’s Ryan White HIV/AIDS Program (RWHAP) commemorates Hepatitis Awareness Month and Hepatitis Testing Day to highlight the importance of testing and treating those coinfected with HIV and viral hepatitis.

Although advances in HIV care and treatment result in longer life expectancy for people with HIV, those who are coinfected with HIV and hepatitis C still have a high risk of liver-related illness and death.  Viral hepatitis progresses faster and causes more liver-related health problems among people with HIV than among those who do not have HIV. Approximately 25% of people with HIV are coinfected with hepatitis C.  

From 2010-16, new HCV infections more than tripled, in part due to the opioid epidemic. 

Recent advances in treatment make it possible to win the fight against hepatitis C.  The recently FDA-approved treatment options for hepatitis C, collectively called Direct-Acting Antivirals (DAAs), are a game-changer in the field of hepatitis C care and treatment. 

Previously, the most effective available therapies, which were interferon-based regimens requiring 48 weeks of treatment, were poorly tolerated, and of particular concern for people with HIV/hepatitis C coinfection.  The treatment commonly caused severe drug-to-drug interactions and resulted in a cure for fewer than one in three people who completed treatment. For the first time, persons infected with hepatitis C can be cured, with all-oral, once-daily treatment regimens that last eight-24 weeks; efficacy rates for the these medications are similarly high (above 90%) for both hepatitis C monoinfected and HIV/hepatitis C coinfected people.  In addition, there are minimal side effects or contraindications of these medications. [HHS guidelines recommend that all people with HIV be tested for HCV, with those testing positive be considered for HCV treatment.]

May is Hepatitis Awareness Month and May 19 is Hepatitis Awareness Day

Clinician Resources

HRSA HAB has several resources to assist you as a provider to increase the screening and treatment of your patients with HIV.

• HIV/HCV Coinfection: An AETC National Curriculum.
• Clinician Consultation Center is a clinician-to-clinician hotline that providers can call to receive advice on HCV monoinfection and coinfection management.  

Laura W. Cheever, MD, ScM
Associate Administrator
HRSA HIV/AIDS Bureau

HRSA's AETC National Coordinating Resource Center's (NCRC) viral hepatitis confection topic page presents clinician-focused resources on care and treatment of hepatitis.

HCV/HIV Care Delivery

HRSA's focus on HCV/HIV coinfection care includes development of innovations in care delivery and performance and data monitoring by RWHAP agencies to measure their efforts to deliver and improve services to coinfected individuals. Examples of current activities are outlined below. 

• Integrating Hep C Treatment into HIV Care. An implementation guide, case studies, and a pocket guide featuring innovative practices on HCV treatment within HIV primary care programs. Resources were developed under HRSA's Integrating HIV Innovative Practices (IHIP) and are based on lessons learned from an earlier SPNS research and demonstration project Hepatitis C Treatment Expansion Initiative (2010-2014).
• Jurisdictional Approach to Curing Hepatitis C among HIV/HCV Coinfected People of Color. This HRSA HCV SPNS initiative was initiated in late 2016 to improve HCV services among HIV/HCV-coinfected people of color and is funded under the FY 2016 Secretary’s Minority AIDS Initiative Fund. 

• Curing Hepatitis C among People of Color Living with HIV. This is another SPNS initiative is focused on expanding a full array of services for HCV/HIV coinfected individuals, in collaboration with SAMHSA-funded substance abuse agencies.  

• Performance Measurement. The HRSA HIV/AIDS Bureau has created a framework of resources to support Ryan White programs in monitoring the delivery of HIV care, inclusive of hepatitis. HAB's Performance Measures are comprised of multiple sets, with an adolescent/adult set of measures that includes specific measures addressing hepatitis B screening and vaccination and hepatitis C screening.
• Data Monitoring. HRSA's Ryan White Services Report, the RSR client-level data system, is used by grant recipients and subrecipients to collect performance measure data on hepatitis B screening and vaccination as well as hepatitis C screening.

See more on our Hepatitis Topic Page